医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Samsung Bioepis to Initiate Phase 1 Clinical Trial of SB26 Ulinastatin-Fc Fusion Protein

2018年08月13日 AM08:00
このエントリーをはてなブックマークに追加


 

INCHEON, Korea

Samsung Bioepis Co., Ltd. today announced it will soon begin a Phase 1 study to evaluate SB26 in healthy volunteers. SB26, also known as TAK-671, is a ulinastatin-Fc (UTI-Fc) fusion protein intended to treat severe acute pancreatitis. Non-clinical GLP safety studies performed in monkeys and rats supported early human studies with SB26.

The randomized, double-blind, placebo-controlled, single and multiple dose escalation Phase 1 study is designed to assess the safety, tolerability and pharmacokinetics of intravenous SB26 in healthy volunteers. Results of the Phase 1 study are expected in the third quarter of 2020.

“The upcoming clinical trial marks a major milestone for those of us at Samsung Bioepis, as SB26 is set to become the first novel biologic candidate from our company to enter clinical trials,” said Chul Kim, Senior Vice President and Head of Clinical Sciences Division, Samsung Bioepis. “Acute pancreatitis remains one of the most common gastrointestinal conditions, affecting more patients every year. While mild acute pancreatitis is more easily treatable, severe acute pancreatitis, which affects approximately 20% of patients suffering from acute pancreatitis, can often be fatal. Unfortunately, treatment options remain extremely limited. By leveraging the unique strengths of our partnership with Takeda, we hope to rapidly advance SB26 through clinical trials.”

SB26 is the first therapeutic candidate in the risk-sharing strategic collaboration agreement between Samsung Bioepis and Takeda Pharmaceutical Company Limited (TSE: 4502), which brings together Samsung Bioepis’ agile biologics development platform with Takeda’s best-in-class experts in drug development to co-fund and collaboratively develop innovative therapies representing meaningful value to patients who need them.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world’s leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that includes six late-stage candidates that cover the therapeutic areas of immunology, oncology and diabetes. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180812005033/en/

CONTACT

Samsung Bioepis Co., Ltd.
MEDIA
Mingi Hyun
+82-31-8061-1594
mingi.hyun@samsung.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc